INNOVIVA, INC. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
INNOVIVA, INC. (INVA) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $3.27 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-02-25
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.27M.
- 2025-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $3.62M.
- 2025-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.08M.
- 2025-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $4.62M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2025-12-31 | $3.27M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.62M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.08M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $4.62M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $5.16M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.68M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $6.22M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $6.74M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $7.27M 10-K · filed 2025-02-26 |
| 2023-09-30 | $7.78M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $8.30M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $8.81M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $9.33M 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $9.89M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $10.45M 10-Q · filed 2022-07-27 |
| 2022-03-31 | $10.96M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $38.83M 10-K · filed 2023-02-28 |
| 2021-09-30 | $41.19M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $43.49M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $45.76M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $47.97M 10-K/A · filed 2022-03-17 |
| 2020-09-30 | $50.13M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $52.25M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $54.33M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $56.36M 10-K · filed 2021-02-25 |
| 2019-09-30 | $58.59M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $60.56M 10-Q · filed 2019-07-24 |
| 2019-03-31 | $62.49M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $64.38M 10-K · filed 2020-02-19 |
| 2018-09-30 | $66.23M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $70.71M 10-Q · filed 2018-07-26 |
| 2018-03-31 | $72.64M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $77.87M 10-K · filed 2019-02-19 |
| 2017-09-30 | $80.03M 10-Q · filed 2017-11-03 |
| 2016-12-31 | $12.08M 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |